Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer

Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer

(2020) Won-Ji Ryu et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer

(2019) Jieun Park et al.   Scientific Reports

Gemcitabine‐induced epithelial‐mesenchymal transition‐like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal‐like phenotype

(2019) Mehdi El Amrani et al.   MOLECULAR CARCINOGENESIS

KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway

(2019) Zhiyan Ruan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer

(2018) Philipp Manegold et al.   Cancers

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer

(2018) Yeo Wool Kang et al.   CANCER LETTERS

β‐Catenin‐RAS interaction serves as a molecular switch for RAS degradation via GSK3β

(2018) Sang‐Kyu Lee et al.   EMBO REPORTS

Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation

(2016) Pu-Hyeon Cha et al.   Nature Chemical Biology

KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer

(2016) Yong-Hee Cho et al.   Oncotarget

Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling

(2016) Bao-Qing Xu et al.   Oncotarget

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

(2015) J. Downward   CLINICAL CANCER RESEARCH

The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma

(2015) Priya Pai et al.   Molecular Oncology

Drugging the undruggable RAS: Mission Possible?

(2014) Adrienne D. Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)

(2010) Di Marco   ONCOLOGY REPORTS

Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer

(2009) T. Arumugam et al.   CANCER RESEARCH